Maridebart cafraglutide clinical trials
Maridebart cafraglutide is named as an intervention in 17 current clinical trials in our USA, Japan, Canada, Poland, Germany, Czechia, Spain, Australia, UK, Italy, South Korea, France, Brazil, Belgium, Sweden, Denmark, Switzerland, Austria, Taiwan, China, Netherlands, Portugal, Turkey, Mexico and Singapore registers. 6 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Amgen. The most-studied condition is Obesity. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
How Maridebart cafraglutide works
All drug targets →- OverweightPhase 3
- Obesity disorderPhase 3
- Obstructive sleep apnea syndromePhase 3
- Type 2 diabetes mellitusPhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314751, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13316, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Maridebart cafraglutide
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Maridebart cafraglutide
17 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Maridebart cafraglutide in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Maridebart cafraglutide. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus
2025-524788-19-00 · Nutritional and Metabolic Diseases
|
Phase 3 | Ongoing | Amgen Inc | Germany, Hungary, Czechia + 3 more |
Conditions studied with Maridebart cafraglutide
13 conditionsAll 13 conditions
| Condition (as registered) | Trials |
|---|---|
| Obesity | 9 |
| Overweight | 6 |
| Diabetes Mellitus, Type 2 | 2 |
| Obstructive Sleep Apnea | 2 |
| Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | 1 |
| Heart Failure With Preserved Ejection Fraction | 1 |
| Heart Failure With Mildly Reduced Ejection Fraction | 1 |
| Atherosclerotic Cardiovascular Disease | 1 |
| Type 2 Diabetes Mellitus | 1 |
| Overweight or Obesity and Elevated Liver Fat | 1 |
| Obesity or Overweight | 1 |
| Type 2 Diabetes Mellitus (T2DM) | 1 |
| Obesity Disease | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Amgen | 17 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Maridebart cafraglutide trials
How many clinical trials are testing Maridebart cafraglutide?
17 current trials in our USA, Japan, Canada, Poland, Germany, Czechia, Spain, Australia, UK, Italy, South Korea, France, Brazil, Belgium, Sweden, Denmark, Switzerland, Austria, Taiwan, China, Netherlands, Portugal, Turkey, Mexico and Singapore registers name Maridebart cafraglutide (also registered as AMG 133) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Maridebart cafraglutide trials recruiting patients?
Yes. 6 of the 17 trials are recruiting: 6 with sites in USA, 3 with sites in Japan, 4 with sites in Canada, 1 with sites in Poland, 1 with sites in Germany, 1 with sites in Czechia, 1 with sites in Spain, 2 with sites in Australia, 2 with sites in UK, 1 with sites in Italy, 1 with sites in South Korea, 1 with sites in France, 1 with sites in Brazil, 1 with sites in Belgium, 1 with sites in Sweden, 1 with sites in Denmark, 1 with sites in Switzerland, 1 with sites in Austria, 1 with sites in Taiwan, 1 with sites in China, 1 with sites in Netherlands, 1 with sites in Portugal, 1 with sites in Turkey and 1 with sites in Mexico. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Maridebart cafraglutide clinical trials?
The lead sponsor is Amgen. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Maridebart cafraglutide works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Maridebart cafraglutide works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Maridebart cafraglutide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.